Objective To investigate the cost-effect of Vancomycin and Linezolid in the treatment of MRSA infection, providing practical basis for clinical drug use. Methods Patients admitted into our hospital duringfrom January 2014 to March 2016 were retrospectively analyzed. All cases of MRSA infection using Vancomycin or (and) Linezolid as antibiotic therapy were included in this study. The efficacy and pharmacogenomics of Linezolid and Vancomycin in treatment of MRSA were recorded. Results Incidence of renal function in linezolid Linezolid group was significantly lower than that in Vancomycin group (P < 0.05). Time duration of antibiotics usage in Vancomycin group were prolonged compared with linezolid Linezolid group [(7.04 ± 0.45) d vs (5.12 ± 0.47), P < 0.05]. Longer hospitalization stay was also identified in Vancomycin group compared with Linezolid group [(10.76 ± 0.53) d vs (8.06 ± 0.58) d, P < 0.05]. DUI of Vancomycin and Linezolid were both less than 1, while therapeutic effectiveness and cost-effectiveness ratio (C/E) of Linezolid was significantly higher than that in Vancomycin group (P < 0.05).Conclusion Linezolid may be a better choice for treatment of MRSA due to better cost-effectiveness, efficacy and safety compared with Vancomycin.

OBJECTIVE To investigate the distribution and antibiotic resistance of pathogens isolated from hospitalized patients with lower respiratory tract infections,so as to provide basis for reasonable use of antibiotics.METHODS The pathogens isolated from sputum samples from hospitalized patients with lower respiratory tract infections from 2007 to 2010 were collected,the species and drug resistance of those isolates were retrospectively analyzed.RESULTS Of the hospitalized cases with lower respiratory tract infections,gram-negative bacilli infections accounted for 57.9%,fungi accounted for 22.6%,and gram-positive cocci accounted for 19.5%;the top five pathogens isolated were in order as follows:Klebsiella pneumoniae(20.4%),Candida albicans(16.0%),Pseudomonas aeroginosa(14.2%),Staphylococcus aureus(10.6%),and Escherichia coli(10.0%);the main pathogens varied in drug resistance to common antibiotics.CONCLUSION It is necessary to strengthen the surveillance and control of the pathogens causing lower respiratory tract infections so as to prevent the spread and prevalence of resistant strains.